Intellectual Property
Oct. 10, 2017
Drugmaker asks federal judge to invalidate rival company’s patents
Amgen Inc. asked a federal judge to invalidate numerous patents claimed by rival Genentech Inc. so it can create a cheaper, generic version of a popular cancer drug.
Drugmaker Amgen Inc. has asked a federal judge to invalidate numerous patents claimed by rival Genentech Inc. so it can create a cheaper, generic version of a popular cancer drug.
Amgen's lawsuit is seeking declaratory judgment on patent non-infringement, invalidity and unenforceability against 27 patents claimed by Genentech.
The patents are associated with Genentech's Avastin brand of a biologi...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$895, but save $100 when you subscribe today… Just $795 for the first year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In